Business Context and Reporting Period
Oncolytics Biotech Inc. is a development-stage biopharmaceutical company focused on REOLYSIN®, an oncolytic virus therapy for Ras-mediated cancers. This Form 6-K reports financial results and operational highlights for the three and six-month periods ended June 30, 2008. The company has not been profitable since its inception in 1998 and expects to continue incurring substantial losses as it advances clinical trials.
Key Financial Metrics
| Metric | Q2 2008 (3 Months) | Q2 2007 (3 Months) | YTD 2008 (6 Months) | YTD 2007 (6 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(5,254,530) | $(3,837,244) | $(8,648,903) | $(8,047,335) |
| Loss Per Share (Basic/Diluted) | $(0.13) | $(0.09) | $(0.21) | $(0.20) |
| Research & Development Expenses | $4,046,904 | $3,031,706 | $6,440,301 | $6,487,420 |
| Operating Expenses | $1,319,498 | $992,307 | $2,370,392 | $1,899,023 |
| Cash and Cash Equivalents (End of Period) | $6,715,096 | $6,923,889 | $6,715,096 | $6,923,889 |
| Total Cash Resources (incl. Short-term Investments) | $17,930,270 | $31,533,000 | $17,930,270 | $31,533,000 |
| Working Capital | $14,267,085 | $22,732,987 | $14,267,085 | $22,732,987 |
| Long-Term Debt | $0 | $150,000 | $0 | $150,000 |
Note: Financial data for 2007 has been restated due to the early adoption of CICA Handbook Section 3064 regarding Goodwill and Intangible Assets.
Material Changes vs. Prior Period
- Net Loss Increase: Q2 2008 net loss increased by approximately 37% compared to Q2 2007, driven primarily by higher Research and Development (R&D) and operating expenses.
- R&D Expenses: Q2 R&D expenses rose to $4.05 million from $3.03 million. This increase was due to higher manufacturing costs (completing 40-litre production runs vs. 20-litre runs in 2007) and increased clinical trial expenses as the number of enrolling trials grew from six to eight.
- Operating Expenses: Increased to $1.32 million in Q2 2008 from $992,000 in Q2 2007, largely due to higher public company-related expenses (professional fees and investor relations) associated with corporate expansion.
- Cash Position: Total cash resources decreased from $31.5 million at the end of Q2 2007 to $17.9 million at the end of Q2 2008. The company reported cash usage from operating activities of $7.2 million for the six months ended June 30, 2008.
- Accounting Change: The company adopted CICA Section 3064 on April 1, 2008, requiring the expensing of third-party legal costs for patents rather than capitalizing them. This resulted in a restatement of prior periods, increasing reported net losses and reducing intellectual property assets on the balance sheet.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Clinical Progress: Management highlighted "strong" clinical results, including durable responses in head and neck cancer patients and stable disease in sarcoma patients. The 200th patient was treated with REOLYSIN® shortly after the quarter end.
- Manufacturing: Successfully transferred cGMP production to SAFC Pharma at the 40-litre scale. Development of 100-litre scale-up and lyophilization is ongoing.
- Cash Burn Rate: Management estimates an average monthly cash usage of $1.66 million for 2008. They believe current capital resources are adequate to fund operations well into 2009.
- Capital Strategy: A base shelf prospectus was filed on June 16, 2008, allowing for the distribution of up to $150 million in securities to facilitate future fundraising.
Risks and Contingencies
- Development Stage Risk: As a development-stage company, Oncolytics has no commercial revenue and relies on equity financing. There is no assurance that REOLYSIN® will prove safe or effective or receive regulatory approval.
- Liquidity Risk: The company may need to raise additional capital. Market conditions for biotechnology securities are volatile, and there is no guarantee that funds will be available when needed.
- Accounting Policy Risk: Future intellectual property expenditures will be expensed as incurred until specific capitalization criteria are met, which may impact future reported earnings.
Key Facts for Investor Verification
- Cash Runway: Verify if the estimated $1.66 million monthly burn rate remains accurate given the expansion of clinical trials and manufacturing activities.
- Clinical Trial Enrollment: Confirm the pace of patient enrollment in the U.K. and U.S. Phase II trials for head and neck cancer and the U.S. sarcoma trial.
- Manufacturing Scale-Up: Monitor the progress of the 100-litre scale-up and lyophilization studies, which are critical for future commercialization.
- Capital Markets: Assess the company's ability to access capital markets if the current cash reserves deplete faster than anticipated, noting the $150 million shelf registration.
- Patent Portfolio: Review the impact of the new accounting standard on future R&D expense reporting and the status of the 180+ patents secured.